Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
Citation
Karacin, C., Eren, T., Zeynelgil, E., Imamoglu, G. I., Altinbas, M., Karadag, I., Basal, F. B., Bilgetekin, I., Sutcuoglu, O., Yazici, O., Ozdemir, N., Ozet, A., Yildiz, Y., Esen, S. A., Ucar, G., Uncu, D., Dinc, B., Aykan, M. B., Erturk, İ., Karadurmus, N., … Oksuzoglu, O. B. (2021). Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future oncology (London, England), 17(33), 4447–4456. https://doi.org/10.2217/fon-2021-0597Abstract
Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 mu g/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.
Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immunotherapy alone.
